INTRODUÇÃO: O objetivo do presente estudo é apresentar dados morfométricos da fenda palpebral e da função do músculo levantador da pálpebra superior, ao longo de 6 meses de seguimento, após a aplicação da toxina botulínica tipo A, em pacientes com retração palpebral nas fases aguda e crônica da orbitopatia distireoidiana. MÉTODOS: Estudo prospectivo, no qual foram incluídos 24 indivíduos, divididos em dois grupos, agudos (n=12) e crônicos (n=12). Foram submetidos à aplicação de toxina botulínica na dose de 5 UI/0,1 ml em uma das pálpebras superiores e seguidos por 6 meses. A avaliação palpebral foi registrada por meio de captação de imagens com uma câmera filmadora de vídeo conectada a um microcomputador. Os valores médios obtidos nos diferentes momentos analisados foram comparados entre os dois grupos. RESULTADOS: A maioria dos pacientes apresentou melhora da retração da pálpebra superior, com redução média de 3,05 mm no grupo agudo e 3,81 mm no grupo crônico. Esta redução foi significativa até 1 mês no grupo agudo e até 3 meses no grupo crônico. Houve diminuição da função do músculo levantador e da diferença entre as áreas lateral e medial da fenda palpebral nos olhos tratados em ambos os grupos. No olho contralateral, houve aumento significativo da fenda palpebral até 2 semanas após a aplicação. Não houve diferença na freqüência dos efeitos colaterais entre os 2 grupos. CONCLUSÕES: A injeção de 5 unidades foi eficaz na redução da retração e da função do músculo levantador e na melhora do contorno palpebral superior, nos pacientes na fase aguda e crônica da orbitopatia distireoidiana, embora esta melhora tenha sido menos duradoura no grupo agudo / INTRODUCTION: The objective of this study is to compare morphometric data of the eyelid fissure and the levator muscle function after transcutaneous injection of botulinum toxin type A with six-month follow-up in patients with upper eyelid retraction from acute and chronic dysthyroid orbitopathy. METHODS: This was a prospective study that included 24 individuals with dysthyroid orbitopathy, divided into two groups, acute (n=12) and chronic (n=12). They were given a 5 UI/0,1 ml dose of botulinum toxin in the upper eyelid and examined periodically for 6 months. Clinical eyelid examination was performed and recorded using a video camera connected to a microcomputer. Mean values taken at different follow-up points were compared for the two groups. RESULTS: Most patients experienced marked improvement in upper eyelid retraction, with a mean reduction of 3.05 mm in acute group and 3.81 mm in chronic group. This reduction was significantly smaller during 1 month in acute group and during 3 months in chronic group. Reduction in levator function and in the difference between lateral and medial lid fissure measurements was observed in both groups. Measurements of the contralateral eye increased up to 2 weeks after the application. No difference was observed between the study groups with regard to the observed side effects. CONCLUSIONS: A single 5-unit botulinum toxin injection improved upper eyelid retraction, reduced levator function, and produced an adequate lid contour in patients with acute and chronic dysthyroid orbitopathy. The effect lasts longer in patients with chronic disease than in patients with acute disease.

Submitted by (lucia.rodrigues@ufrpe.br) on 2016-06-08T13:37:15Z No. of bitstreams: 1 Jaciel Benedito de Oliveira.pdf: 2001810 bytes, checksum: 849f2538ec8321a9c6a102564bb281e9 (MD5) / Made available in DSpace on 2016-06-08T13:37:15Z (GMT). No. of bitstreams: 1 Jaciel Benedito de Oliveira.pdf: 2001810 bytes, checksum: 849f2538ec8321a9c6a102564bb281e9 (MD5) Previous issue date: 2014-02-28 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES / The aim of this study was to observe the morphometric, histological and histométricos aspects of submandibular glands of rats treated with botulinum toxin type A (BTX-A) and with bovine gelatin. We used 80 submandibular glands of adult Wistar rats and divided into three groups: group I, control (n = 14); group II (n = 34) submitted the intraglandular injection of bovine gelatin (0.25 mg); and group III (n = 32) treated with intraglandular injection of botulinum toxin type A (2.5 U). The groups II and III were divided into 3 subgroups according to the day of analysis of glands (7, 15 and 28 days after treatment), when they were removed, heavy and measures immediately for morphometric analysis. Next, were fixed in paraformaldehyde 4 % and processed conventionally for light microscopy, stained in H.E., P.A.S., alcian blue, Gomori trichrome and picrosirius red. Morphometric differences were not observed between subgroups of group III, however in group II there was a significant difference between the three subgroups in the longitudinal length (p = 0.030) and transverse length (p = 0.025), having the gland has shown greater at day 28th after treatment. Histometrically, serous and mucous acini group III, were presented with a smaller diameter compared with the acinithe subgroups treated with bovine gelatina (group II). The wall thickness of the striated duct Group III was lower than in other. Histologically, there was a greater amount of cytoplasmic vacuolization in group III. addition to the greater spacing between the acini. Thus, we conclude that botulinum toxin type A interferes with the structural organization of the submandibular glands, promoting a reduction in the diameter of serous acini and in wall thickness striated ducts, macroscopically but this difference was not significant. / O objetivo deste trabalho foi observar os aspectos morfométricos, histométricos e histológicos das glândulas submandibulares de ratas tratadas com toxina botulínica tipo A (BTX-A) e com gelatina bovina. Foram utilizadas 80 glândulas submandibulares de ratas Wistar adultas e divididas em três grupos: grupo I controle (n = 14); grupo II (n = 34) submetidas a injeção intraglandular de gelatina bovina (0,25 mg); e grupo III (n = 32) tratadas com injeção intraglandular de toxina botulínica tipo A (2,5 U). Os grupos II e III foram divididos em 3 subgrupos de acordo com o dia de análise das glândulas (7, 15 e 28 dias após o tratamento), quando foram removidas, imediatamente pesadas e medidas para análise morfométrica. A seguir, foram fixadas em paraformaldeído 4% e processadas convencionalmente para microscopia de luz, coradas em H.E, P.A.S., alcian blue, tricrômico de Gomori e picrossirius red. Testes estatísticos dos resultados morfométricos e histométricos obtiveram o nível de significância de 0,05 (5%). Morfometricamente não foram observadas diferenças entre os subgrupos do grupo III, entretanto no grupo II houve diferença significativa entre os três subgrupos no comprimento longitudinal (p = 0,030) e comprimento transversal (p = 0,025), tendo a glândula se apresentado maior no 28º dia após o tratamento. Histometricamente, os ácinos serosos e mucosos do grupo III, apresentaram-se com diâmetro menor quando comparado com o ácinos dos subgrupos tratados com gelatina bovina (grupo II). A espessura da parede do ducto estriado do grupo III foi menor que nos demais. Histologicamente, observou-se a maior quantidade de vacuolizações citoplasmáticas no grupo III, além do maior espaçamento entre os ácinos. Dessa forma, concluímos que a toxina botulínica tipo A interfere na organização estrutural das glândulas submandibulares, promovendo uma diminuição no diâmetro dos ácinos serosos e na espessura da parede dos ductos estriados, mas que macroscopicamente tal diferença não se mostrou significante.

O Acidente Vascular Cerebral (AVC) é um quadro de alta incidência e uma das principais causas de incapacidade no mundo. Uma de suas complicações frequentes e de grande impacto na funcionalidade é a Síndrome do Ombro Doloroso Hemiplégico (SODH). O presente trabalho consiste em revisar a literatura a respeito da eficácia do tratamento da SODH com toxina botulínica tipo A (TXB-A). Foram pesquisados os bancos de dados eletrônicos PubMed e ISI web of Science, no período de 1996 a 2014. Incluímos os estudos tipo ensaio clínico duplo-cego, randomizado e aleatorizado que utilizaram a TXB-A como tratamento da SODH. Os artigos deveriam obter pontuação 3 ou superior pelos critérios de Jadad. Seis estudos foram encontrados e dois foram considerados de baixa qualidade. Os quatro artigos restantes possuíam 114 participantes no total. Três autores avaliaram os artigos de forma independente quanto aos critérios de inclusão. A extração de dados incluiu as características dos pacientes, dose e marca comercial da TXB-A utilizada, músculos e efeitos na avaliação da dor. Houve grande variação de dose, técnicas de aplicação e músculos tratados, bem como das intervenções após a aplicação. Três estudos demonstraram efeitos positivos do tratamento da dor e função do membro superior. A meta-análise não pode ser realizada, pois a informação quantitativa necessária foi indisponível. Os resultados da literatura são discordantes e apesar dos indícios serem favoráveis, não há resultados estatisticamente significantes para corroborar tal prática. Maior investigação e pesquisa são necessários para definir a indicação da TXB-A como tratamento da SODH. Mesmo assim, esta abordagem pode ser considerada particularmente quando a espasticidade é relevante. A intervenção pode ser realizada como uma alternativa ou ser utilizada em combinação com outros tratamentos. Para melhores resultados, mais de um músculo deve ser alvo, preferencialmente os músculos peitoral maior e subescapular. / The Stroke presents a high incidence and is a major cause of disability the in the world. One of it`s frequent complications and a cause of great loss of quality of life is the post-stroke shoulder pain (PSSP). The purpose of this study is to explore the effectiveness of botulinum neurotoxin type A (BoNT-A) in the treatment of PSSP. The electronic databases PubMed and ISI web of Science were searched from 1996 to 2014. We included double-blind randomized controlled trials that used BoNT-A for the treatment of PSSP in spastic hemiplegic patients. Articles should be scored 3 or more with the Jadad criteria. Six studies fulfilled the first search and two were considered low quality. The four remaining studies comprised 114 participants. Three authors independently evaluated articles eligible for inclusions. Data extracted included patient characteristics, doses and types of commercialized BoNT-A used, muscles injected, and effects on pain evaluation. There was a large variation in doses, injection techniques and treated muscles, as well as post-injection interventions. Three studies demonstrated positive effects of BoNT-A in the treatment of pain or upper limb functioning. Meta-analysis was not performed because of unavailable quantitative data. Literature results are discordant and despite evidence be favorable, there are no statistically significant results to support this practice. Further investigation and research is needed to define the indication of BoNT-A on PSSP. Nevertheless, this approach can be seen particularly when the spasticity is relevant. The intervention may be performed as an alternative or used in combination with other treatments. For best results, more than one muscle should be targeted, preferably the pectoralis major and subscapularis muscles.

INTRODUÇÃO: A paralisia facial é constrangedora tanto do ponto de vista funcional quanto estético. Esta pesquisa teve por objetivo verificar o efeito da terapia miofuncional em pacientes com paralisia facial de longa duração associada à aplicação de toxina botulínica. MÉTODOS: Foram tratados vinte e cinco pacientes, divididos em dois grupos. Os pacientes do grupo A receberam quatro sessões de terapia miofuncional antes da aplicação de toxina botulínica e os pacientes do grupo B simultaneamente à aplicação. A terapia foi composta por manobras isométricas e isotônicas passivas, intra e extraorais, além de exercícios de resistência. RESULTADOS: Após a terapia miofuncional os pacientes apresentaram aumento significativo da mobilidade do lado paralisado da face, do índice de satisfação do paciente com a face, do Índice Funcional da Face (IFF) e do Índice de Bem-Estar Social (IBES). O grupo de pacientes que realizaram a terapia miofuncional previamente, apresentou freqüência significativamente maior de dificuldade para falar, enquanto o grupo que realizou a terapia miofuncional a partir da data da aplicação de toxina botulínica, apresentou freqüência significativamente maior de dificuldade para mastigar. A terapia miofuncional promove simetria facial; satisfação dos pacientes com a face, funcionalidade oromiofacial, qualidade de vida e deve ser realizada antes e após aplicação de toxina botulínica para reduzir os possíveis efeitos adversos. / INTRODUCTION: The facial paralysis is constraining so much of the functional point of view as aesthetic. This research had for goal verified the myofunctional therapy effect in patients with long-standing facial paralysis associate to the botulinum toxin application. METHODS: Twenty-five patients were treated, divided into two groups. The patients from the group A received four sessions of myofunctional therapy before the toxin botulinum application and the patients from the group B received it simultaneously to the application. The therapy was composed by isometric and passive isotonic maneuvers, inside and outside oral, and resistance exercises. RESULTS: After the myofuncional therapy the patients presented significant increase of the mobility of the paralyzed side, of the patient satisfaction index with the face, Functional Index of the Face (IFF) and of the Index of Social Welfare (IBES). The group of patient that accomplished the myofuncional therapy previously presented significantly larger frequency of talking difficulty, while the group that accomplished the miofuncional therapy from the toxin botulínica application date presented significantly larger frequency of chewing difficulty. The myofuncional therapy promotes facial symmetry; patients satisfaction with the face, myofuncional functionality, life quality, and should be accomplished before and after toxin botulínica application to reduce the possible adverse effects.

This Master's thesis focuses on Occupational therapy for patients after application of botulinum toxin to upper limb. The aim of the thesis was to evaluate and compare a progress of functional independence in patients after acquired brain injury. There were twenty patients involved in the research, who were further divided into two groups and separated by ten people in each group. Both groups underwent the application of botulinum toxin whereas the experimental group A went through the occupational therapy. The control group had ordinary rehabilitation at home and without any occupational intervention for the duration of twelve week under guided self-rehabilitation contract of spastic paresis, so-called GSC. A programme of the group A included over the counter rehabilitation outpatient occupational therapy. The patients attended the course twice a week for the duration of four weeks. Afterwards, they received a home programme for the duration of eight weeks, during which they had two examinations at occupational therapy. All the participants were evaluated by Global Subjective Self-Assessment which is focused on spasticity. There were further evaluated according to Functional Independece Measure and modified Frenchay Arm Test. The experimental group with outpatient occupational therapy was...

Made available in DSpace on 2016-01-26T18:55:37Z (GMT). No. of bitstreams: 1 Sergio Vilhegas.pdf: 700648 bytes, checksum: 61199638be80e4484e7e0b1e44be0387 (MD5) Previous issue date: 2013-09-23 / The aim of this study was to evaluate the analgesic effects of botulinum toxin as an adjunct in the control of postoperative pain in dogs. In a blinded study, sixteen dogs undergoing mastectomy were randomly assigned to two groups of 08 animals each and received 7U kg-1 of botulinum toxin diluted in 10mL of saline and administered 1mL in each breast, subcutaneously (TXB) or 1mL of saline administered in each breast (Control), subcutaneously. After twenty four hours, pre-anesthetic medication was intramuscular (IM) acepromazine (0.03mg kg-1) in combination with morphine (0.3mg kg-1). Anesthesia was induced with intravenously (IV) propofol (4 to 5mg kg-1) and maintained with isoflurane. The analgesic intra-operative support was provided by IV continuous rate morphine (0.1mg kg-1h-1). Heart rate, respiratory rate, systolic arterial blood pressure, oxicapnografy and end-tidal concentration of isoflurane were evaluated during the surgery. Postoperative analgesia was assessed during the first 72 hours after the tracheal extubation using a Visual Analog Scale (VAS) and Glasgow Modified Scale (GMS). Rescue analgesia with morphine (0.5mg kg-1 IM) was performed if the evaluation score exceeded 50% of VAS and/or 30% of GMS during the postoperative period. The pain scores were lower in TXB group than in Control group from 8 to 60 hours and from 12 to 60 hours post-extubation, according to VAS and GMS scales, respectively. Postoperative rescue analgesia was lower in the TXB group (2 of 8 dogs), when compared with Control group (7 of 8 dogs). Cardiopulmonary established was detected in both treatment groups. Preemptive botulinum toxin administration is a satisfactory alternative to post-operative management in dogs undergoing mastectomy. / Este estudo teve como objetivo avaliar a administração da toxina botulínica como adjuvante do controle da dor pós-operatória de cães. Em delineamento cego, dezesseis cadelas, encaminhadas para mastectomia radical foram distribuídas aleatoriamente em dois tratamentos: TXB (n=8) administração de 7U kg-1 de toxina botulínica, diluída em 10 mL de solução salina, sendo administrado 1mL em cada mama, por via subcutânea (SC); Controle (n=8) administração de 10 mL de solução salina (1mL em cada mama, SC). Vinte e quatro horas após, os animais foram encaminhados para cirurgia, sendo tranquilizados com acepromazina (0,03mg kg-1) associada à morfina (0,3mg kg-1), por via intramuscular (IM). Transcorridos vinte minutos, iniciou-se a infusão contínua intravenosa (IV) de morfina (0,1mg kg-1 h-1) que foi mantida durante toda a cirurgia. A indução anestésica foi realizada com propofol (4-5mg kg-1, IV), seguindo-se a manutenção da anestesia com isofluorano. Parâmetros avaliados: frequência cardíaca e respiratória, pressão arterial sistólica, oxicapnografia e concentração final expirada de isofluorano. No pós-operatório o grau de analgesia foi mensurado durante 72 horas após a extubação traqueal, utilizando-se a Escala Analógica Visual (EAV) e Escala de Glasgow Modificada (EGM). Analgesia de resgate foi feita com morfina (0,5mg kg-1 IM) em casos do escore de dor ser superior a 50% da EAV e/ou 33% da EGM. Os escores de dor foram inferiores no tratamento TXB de 8 a 60 horas na EAV e de 12 a 60 horas na EGM. A necessidade de suplementação analgésica foi inferior no gruo TXB (2 de 8 animais) em relação ao grupo Controle (7 de 8 animais). Estabilidade cardiorrespiratória foi observada em ambos os tratamentos. A administração preemptiva de toxina botulínica representa uma alternativa viável para o controle da dor pós-mastectomia em cadelas.

Made available in DSpace on 2016-07-18T17:53:12Z (GMT). No. of bitstreams: 1 Sergio Vilhegas.pdf: 700648 bytes, checksum: 61199638be80e4484e7e0b1e44be0387 (MD5) Previous issue date: 2013-09-23 / The aim of this study was to evaluate the analgesic effects of botulinum toxin as an adjunct in the control of postoperative pain in dogs. In a blinded study, sixteen dogs undergoing mastectomy were randomly assigned to two groups of 08 animals each and received 7U kg-1 of botulinum toxin diluted in 10mL of saline and administered 1mL in each breast, subcutaneously (TXB) or 1mL of saline administered in each breast (Control), subcutaneously. After twenty four hours, pre-anesthetic medication was intramuscular (IM) acepromazine (0.03mg kg-1) in combination with morphine (0.3mg kg-1). Anesthesia was induced with intravenously (IV) propofol (4 to 5mg kg-1) and maintained with isoflurane. The analgesic intra-operative support was provided by IV continuous rate morphine (0.1mg kg-1h-1). Heart rate, respiratory rate, systolic arterial blood pressure, oxicapnografy and end-tidal concentration of isoflurane were evaluated during the surgery. Postoperative analgesia was assessed during the first 72 hours after the tracheal extubation using a Visual Analog Scale (VAS) and Glasgow Modified Scale (GMS). Rescue analgesia with morphine (0.5mg kg-1 IM) was performed if the evaluation score exceeded 50% of VAS and/or 30% of GMS during the postoperative period. The pain scores were lower in TXB group than in Control group from 8 to 60 hours and from 12 to 60 hours post-extubation, according to VAS and GMS scales, respectively. Postoperative rescue analgesia was lower in the TXB group (2 of 8 dogs), when compared with Control group (7 of 8 dogs). Cardiopulmonary established was detected in both treatment groups. Preemptive botulinum toxin administration is a satisfactory alternative to post-operative management in dogs undergoing mastectomy. / Este estudo teve como objetivo avaliar a administração da toxina botulínica como adjuvante do controle da dor pós-operatória de cães. Em delineamento cego, dezesseis cadelas, encaminhadas para mastectomia radical foram distribuídas aleatoriamente em dois tratamentos: TXB (n=8) administração de 7U kg-1 de toxina botulínica, diluída em 10 mL de solução salina, sendo administrado 1mL em cada mama, por via subcutânea (SC); Controle (n=8) administração de 10 mL de solução salina (1mL em cada mama, SC). Vinte e quatro horas após, os animais foram encaminhados para cirurgia, sendo tranquilizados com acepromazina (0,03mg kg-1) associada à morfina (0,3mg kg-1), por via intramuscular (IM). Transcorridos vinte minutos, iniciou-se a infusão contínua intravenosa (IV) de morfina (0,1mg kg-1 h-1) que foi mantida durante toda a cirurgia. A indução anestésica foi realizada com propofol (4-5mg kg-1, IV), seguindo-se a manutenção da anestesia com isofluorano. Parâmetros avaliados: frequência cardíaca e respiratória, pressão arterial sistólica, oxicapnografia e concentração final expirada de isofluorano. No pós-operatório o grau de analgesia foi mensurado durante 72 horas após a extubação traqueal, utilizando-se a Escala Analógica Visual (EAV) e Escala de Glasgow Modificada (EGM). Analgesia de resgate foi feita com morfina (0,5mg kg-1 IM) em casos do escore de dor ser superior a 50% da EAV e/ou 33% da EGM. Os escores de dor foram inferiores no tratamento TXB de 8 a 60 horas na EAV e de 12 a 60 horas na EGM. A necessidade de suplementação analgésica foi inferior no gruo TXB (2 de 8 animais) em relação ao grupo Controle (7 de 8 animais). Estabilidade cardiorrespiratória foi observada em ambos os tratamentos. A administração preemptiva de toxina botulínica representa uma alternativa viável para o controle da dor pós-mastectomia em cadelas.

Neurons depend upon neurotransmitter release through regulated exocytosis to accomplish the immense processing performed within the central nervous system. The SNARE hypothesis points to a family of proteins that are thought to enable the membrane fusion that leads to exocytosis. The secondary structure of SNAP-25 is unique among SNARE proteins in that it has two alpha helical SNARE motifs and a cysteine rich (C85, C88, C90, C92) membrane interacting region but notransmembrane domain. The cysteines may be modified by palmitoylation or oxidation but the role of these modifications in vivo is not well understood. Our goal is to elucidate possible regulatory roles of SNAP-25 that relate to its unique structure and these reversible modifications. However, the study of SNAP-25 in reconstituted systems is hampered by a lack of readily available palmitoylated SNAP-25. A method for in vitro palmitoylation of SNAP-25 by HIP14, a neuronal acyltransferase, is described along with the application of a biotinylation streptavidin assay to verify palmitoylation. Palmitoylation increases the extent to which SNAP-25 interacts with lipids as observed with an environment sensitive trpytophan fluorescence assay. Palmitoylation also alters the phase transition of DPPC lipids differently than unpalmitoylated SNAP-25.This effect on the membrane may influence fusion events. Oxidation of the cysteine residues may be responsible for the sensitivity of SNAP-25 to reactive oxygen species. Our data suggests that, when oxidized, SNAP-25 does not interact with membranes to the same extent as palmitoylated SNAP-25. This may provide a mechanism for reducing exocytosis during oxidative stress. Also, oxidized SNAP-25 is not susceptible to Botulinum Neurotoxin E. The effects of oxidation and palmitoylation on the protein interactions of SNAP-25 may shed light on its role in the SNARE complex and membrane fusion.

On a group level, satisfaction with botulinum neurotoxin (BoNT) treatment in neurological indications is high. However, it is well known that a relevant amount of patients may not respond as expected. The aim of this study is to evaluate the BoNT treatment outcome on an individual level using a statistical single-case analysis as an adjunct to traditional group statistics. The course of the daily perceived severity of symptoms across a BoNT cycle was analyzed in 20 cervical dystonia (CD) and 15 hemifacial spasm (HFS) patients. A parametric single-case autoregressive integrated moving average (ARIMA) time series analysis was used to detect individual responsiveness to BoNT treatment. Overall, both CD and HFS patients significantly responded to BoNT treatment with a gradual worsening of symptom intensities towards BoNT reinjection. However, only 8/20 CD patients (40%) and 5/15 HFS patients (33.3%) displayed the expected U-shaped curve of BoNT efficacy across a single treatment cycle. CD (but not HFS) patients who followed the expected outcome course had longer BoNT injection intervals, showed a better match to objective symptom assessments, and were characterized by a stronger certainty to control their somatic symptoms (i.e., internal medical locus of control). In addition to standard evaluation procedures, patients should be identified who do not follow the mean course-of-treatment effect. Thus, the ARIMA single-case time series analysis seems to be an appropriate addition to clinical treatment studies in order to detect individual courses of subjective symptom intensities.

A aplicação de toxina botulínica A no lado não paralisado (LNP) é feita para tratar a assimetria resultante da paralisia facial (PF). As unidades de toxina onabotulinica A (Ona) e toxina abobotulinica A (Abo) não são equivalentes. Comparou-se a taxa de conversão de 1:3 em pacientes com PF. Cinquenta e cinco pacientes (idade entre 16 e 67 anos, 43 mulheres), com PF de longa duração foram tratados de forma aleatória com a aplicação de Ona (n = 25) ou Abo (n = 30) no LNP. Efeitos adversos, simetria facial, satisfação subjetiva e Índice de Incapacidade Facial (IIF) foram avaliados após 1 e 6 meses. Os resultados mostraram que a incidência de efeitos adversos foi maior com Abo (93,3% vs. 64,0%, p = 0,007). Avaliação Clínica do LNP diminuiu após 1 mês e aumentou novamente aos 6 meses, sem diferenças entre os grupos. A nota do lado paralisado (LP) foi menor no grupo Ona antes do tratamento, mas semelhante em ambos os grupos depois do tratamento. A nota do LP aumentou depois de 1 mês, e aos 6 meses foi ainda maior que a nota de prétratamento em ambos os grupos. A avaliação subjetiva melhorou em todos os momentos em comparação com a nota do pré-tratamento e diferiu entre os dois grupos apenas em 1 mês, quando o grupo Abo ficou um pouco mais paralisado. Índice de Função Física (IFF) e Índice de Bem-Estar Social (IBES), subescalas do Índice de Incapacidade Facial (IFF), entre os dois grupos não foram diferentes. Concluímos que ambas as toxinas reduziram a assimetria de forma eficiente em pacientes com FP. Os efeitos adversos foram maiores com Abo na equivalência de 1:3 / Botulinum toxin A injection into the nonparalyzed side (NPS) is used to treat asymmetry resulting from facial palsy (FP). OnabotulinumtoxinA (ONA) and abobotulinumtoxinA (ABO) units are not equivalent. We compared the conversion ratio of 1:3 in patients with FP. Fifty-five patients (aged 16-67 years, 43 women) with long-standing FP were randomly treated with either ONA (n = 25) or ABO (n = 30) injections into the NPS. Adverse effects, facial symmetry, subjective satisfaction, and Facial Disability Index (FDI) were assessed after 1 and 6 months. The results showed that the incidence of adverse effects was higher with ABO (93.3% vs. 64.0%, p = 0.007). Clinical scores of the NPS decreased after 1 month and increased again at 6 months, with no betweengroup differences. Scores of the paralyzed side were lower in the ONA group before treatment, but similar in both groups thereafter. The paralyzed side scores increased after 1 month, and at 6 months were still higher than the pretreatment scores in both groups. Subjective assessment improved at all time points compared to pretreatment score and differed between the two groups only at 1 month, when the ABO group was a bit too paralyzed. The Physical Function and Social/Well-Being Function subscales of the FDI did not differ between the two groups. We conclude that both toxins efficiently reduced asymmetry in patients with FP. Adverse effects were higher with ABO at an equivalence ratio of 1:3